Orchestra BioMed Holdings, Inc. Payments to Acquire Marketable Securities
Orchestra BioMed Holdings, Inc. (OBIO) reported Payments to Acquire Marketable Securities of $56.13 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-10
- Orchestra BioMed Holdings, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $43.00M.
- Orchestra BioMed Holdings, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $13.13M, a 352.27% increase year-over-year.
- Orchestra BioMed Holdings, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $25.63M, a 26.43% increase year-over-year.
- Orchestra BioMed Holdings, Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $47.78M, a 378.38% increase year-over-year.
- Orchestra BioMed Holdings, Inc. payments to acquire marketable securities for fiscal 2025 was $76.31M, a 5.04% increase from fiscal 2024.
- Orchestra BioMed Holdings, Inc. payments to acquire marketable securities for fiscal 2024 was $72.65M, a 48.85% decline from fiscal 2023.
- Orchestra BioMed Holdings, Inc. payments to acquire marketable securities for fiscal 2023 was $142.03M, a 124.30% increase from fiscal 2022.
- Orchestra BioMed Holdings, Inc. payments to acquire marketable securities for fiscal 2022 was $63.32M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $43.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $56.13M 10-Q · filed 2026-08-10 | $81.75M derived: sum of 3 quarters · filed 2026-08-10 | $129.53M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $13.13M 10-Q · filed 2026-05-12 | $38.75M derived: sum of 2 quarters · filed 2026-05-12 | $86.53M derived: sum of 3 quarters · filed 2026-05-12 | $86.53M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $25.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $73.41M derived: sum of 2 quarters · filed 2026-03-12 | $73.41M derived: sum of 3 quarters · filed 2026-08-10 | $76.31M 10-K · filed 2026-03-12 |
| 2025-09-30 | $47.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $47.78M derived: sum of 2 quarters · filed 2026-08-10 | $50.68M 10-Q · filed 2025-11-10 | $70.95M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $2.90M 10-Q · filed 2026-08-10 | $23.17M derived: sum of 3 quarters · filed 2026-08-10 | $33.16M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $2.90M 10-Q · filed 2026-05-12 | $23.17M derived: sum of 2 quarters · filed 2026-05-12 | $33.16M derived: sum of 3 quarters · filed 2026-05-12 | $51.81M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $20.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $30.26M derived: sum of 2 quarters · filed 2026-03-12 | $48.91M derived: sum of 3 quarters · filed 2026-03-12 | $72.65M 10-K · filed 2026-03-12 |
| 2024-09-30 | $9.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $28.64M derived: sum of 2 quarters · filed 2025-11-10 | $52.38M 10-Q · filed 2025-11-10 | $56.34M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $18.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $42.39M 10-Q · filed 2025-08-12 | $46.35M derived: sum of 3 quarters · filed 2025-08-12 | $84.87M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $23.74M 10-Q · filed 2025-05-12 | $27.70M derived: sum of 2 quarters · filed 2025-05-12 | $66.22M derived: sum of 3 quarters · filed 2025-05-12 | $122.27M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $3.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $42.48M derived: sum of 2 quarters · filed 2025-03-31 | $98.54M derived: sum of 3 quarters · filed 2025-03-31 | $142.03M 10-K · filed 2025-03-31 |
| 2023-09-30 | $38.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $94.58M derived: sum of 2 quarters · filed 2024-11-12 | $138.07M 10-Q · filed 2024-11-12 | $201.19M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $56.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $99.55M 10-Q · filed 2024-08-12 | $162.66M derived: sum of 3 quarters · filed 2024-08-12 | $162.66M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $43.49M 10-Q · filed 2024-05-13 | $106.61M derived: sum of 2 quarters · filed 2024-05-13 | $106.61M derived: sum of 3 quarters · filed 2024-05-13 | |
| 2022-12-31 | $63.12M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $63.12M derived: sum of 2 quarters · filed 2024-03-27 | $63.32M 10-K · filed 2024-03-27 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $208.00K 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $208.00K 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |